Arcutis Biotherapeutics Inc (ARQT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Arcutis Biotherapeutics Inc (ARQT) has a cash flow conversion efficiency ratio of 0.012x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($2.24 Million) by net assets ($189.65 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Arcutis Biotherapeutics Inc to measure how much of total assets are equity-financed.
Arcutis Biotherapeutics Inc - Cash Flow Conversion Efficiency Trend (2017–2025)
This chart illustrates how Arcutis Biotherapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Check cash flow quality index of Arcutis Biotherapeutics Inc to evaluate the quality of earnings relative to operating cash generation.
Arcutis Biotherapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Arcutis Biotherapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Shanghai Yuyuan Tourist Mart Co Ltd
SHG:600655
|
0.041x |
|
Rocket Internet SE
HM:RKET
|
N/A |
|
Adani Wilmar Limited
NSE:AWL
|
0.132x |
|
Telefonaktiebolaget LM Ericsson (publ)
ST:ERIC-A
|
0.150x |
|
An Hui Wenergy Co Ltd
SHE:000543
|
0.126x |
|
COL Digital Publishing Group Co Ltd
SHE:300364
|
-0.203x |
|
Acer Incorporated
F:AC5G
|
0.017x |
|
China Leadshine Technology Co Ltd
SHE:002979
|
0.074x |
Annual Cash Flow Conversion Efficiency for Arcutis Biotherapeutics Inc (2017–2025)
The table below shows the annual cash flow conversion efficiency of Arcutis Biotherapeutics Inc from 2017 to 2025. For the full company profile with market capitalisation and key ratios, see ARQT market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $189.48 Million | $-5.62 Million | -0.030x | +95.83% |
| 2024-12-31 | $157.54 Million | $-112.16 Million | -0.712x | +74.45% |
| 2023-12-31 | $88.67 Million | $-247.06 Million | -2.786x | -126.59% |
| 2022-12-31 | $209.58 Million | $-257.71 Million | -1.230x | -109.61% |
| 2021-12-31 | $297.68 Million | $-174.63 Million | -0.587x | -40.45% |
| 2020-12-31 | $270.62 Million | $-113.03 Million | -0.418x | +1.07% |
| 2019-12-31 | $101.46 Million | $-42.84 Million | -0.422x | -171.90% |
| 2018-12-31 | $-23.99 Million | $-14.09 Million | 0.587x | -22.33% |
| 2017-12-31 | $-4.99 Million | $-3.77 Million | 0.756x | -- |
About Arcutis Biotherapeutics Inc
Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. The company's lead product is ZORYVE, a topical roflumilast cream for the treatment of plaque psoriasis and atopic dermatitis. It also develops ZORYVE foam seborrheic dermatitis, and scalp and body psoriasis treatment; ARQ-234, a fusion protein that is a po… Read more